



## A CLINICAL STUDY OF PLACENTA PREVIA –MATERNAL AND PERINATAL OUTCOME

### KEYWORDS

Placenta previa; maternal morbidity; Neonatal mortality.

**DR .NEETA SHARANABASAPPA HARWAL**

**DR.MAHANANDA SHIVARUDRAPPA  
MELKUNDI**

PROFESSOR MAHADEVAPPA RAMPURE MEDICAL  
COLLEGE, KALBURGI

ASSOCIATE PROFESSOR MAHADEVAPPA RAMPURE  
MEDICAL COLLEGE, KALBURGI

### ABSTRACT

**Aim:** analysis of maternal and fetal outcome in pregnancy complicated with placenta previa and to evaluate the potential risk factors

**Methods:** 50 pregnancies with placenta previa during a 2 years study period (2014-2016) were analyzed. The total number of deliveries during the study period was 4759. The data on the potential risk factors compiled; the information on the maternal and neonatal outcome was subjected to appropriate statistical analysis and following deductions provided

**Result:** The incidence of placenta previa was 1.8%. Factors significantly

associated with development of placenta previa were advanced maternal age, number of previous cesarean section, number of previous abortions and multiparity. The complications seen most commonly in the neonatal outcome was prematurity at birth (42.85%) followed by RDS (28.5%) and aspiration (14.2%). 48% of the babies required resuscitation, out of which 24% required further NICU admission. The neonatal mortality calculated was 280/ 1000 live births.

**Conclusion:** In spite of 24 hours emergency services being available, and early diagnosis being at hand, lots more is required to bring down the maternal morbidity and neonatal mortality and morbidity to international standard for us to do justice to the patients.

### Aim of the study

1. To study the risk factors for placenta previa.
2. To study the signs of placenta previa.
3. To study the mode of deliveries
4. To study the maternal and fetal outcome.
5. To study the incidence of placenta previa.

### METHODOLOGY

#### Material of the Study:

Analysis of maternal and neonatal outcome in cases of placenta previa occurring over a period of 2 years from June 2014 to July 2016. This study was carried out at the Basaveshwar Teaching & General Hospital and Sangameshwar Teaching and General Hospital, Gulbarga attached to M.R.Medical College, Gulbarga.

The present study group consisted 50 cases of pregnancies with placenta previa, selected randomly.

#### Inclusion Criteria:

Pregnant women with placenta previa confirmed by ultrasonography and with gestational age beyond 28 weeks were selected irrespective of their parity, type of placenta previa and with a live or dead fetus.

### RESULTS

The total number of in the study period, July 2014 to 2016 are 4759, out of which 233 patients presented with antepartum hemorrhage. Percentage of women presenting with APH is 4.9%. 88 cases of placenta previa were managed, giving an incidence of 1.8%.

Table-1: Incidence of Placenta Previa

Total number of births	4759
Total number of cases of APH	233
Total number of cases of placenta previa	88
Incidence of APH	4.9%
Incidence of placenta previa	1.8%
Total number of perinatal deaths due to various causes	389
Total number of perinatal deaths due to placenta Previa	24
General perinatal mortality rate	18/1000 live births
Perinatal mortality rate in placenta previa	280/ 1000 live births
NICU admissions	12/50(24%)

Maternal deaths due to placenta previa

Nil

The out of our study group of 50 cases of placenta previ 24 cases had minor degree of placenta previa and 26 cases had major degree of placenta previa. 41 cases were delivered by cesarean section, 38 as emergency, 3 as elective and 9 cases delivered vaginally.

In the present study, the following results have been discussed under the following headings:

1. The incidence of placenta previa.
2. Correlation of maternal age and placenta previa.
3. Correlation of parity and placenta previa.
4. Risk factors in placenta previa.
5. Antenatal complications associated with placenta previa&
6. Intra and post-operative complications noted in the cases studied.
7. Mode of delivery.
8. The perinatal morbidity in placenta previa.
9. The perinatal mortality rate.
10. Correlation between perinatal mortality and type of placenta previa.
11. Correlation between perinatal mortality and gestational age.
12. Correlation between perinatal mortality and birth weight of infants.

The results of analysis of the booking status of these 50 women enrolled in the study showed that 30 (60%) cases had been booked with regular ANC, while 20(40%) cases remained unbooked.

Table-2 ANC status

Study	ANC Status			
	Booked		Unbooked	
	No.	Percent	No.	Percent
Percent Study	30	60.00	20	40.00

Regarding the maternal age, the' maximum number of patients i.e., 35 (70%) women were between the age group of 20-29 years, followed in descending order by 8 (16%) women in 30-35 years age group. 6 (12%) women were more than 35 years and one woman (2%) was less than 19 years.

Table-3: Correlation of Parity and Placenta Previa

Parity	No. of cases (n =50)	Percentage

Primi	10	20.00
Multi (2-3)	28	56.00
Grand multi (>4)	12	24.00

Mean Parity = 2.5

In the present study the incidence of placenta previa was highest (56%) in multigravidas (with two to three viable births). The incidence in grand multi's (>4 viable births) was 24% and in primi's it was 20%, clearly depicting that 80% of cases of placenta previa were seen in multi's and grand multiparous women.

**Table - 4 Risk factors for placenta previa**

Risk factor	No. of cases (n =50)	Percentage
Previous Caesarean Section	6	12.00
Previous Abortion	9	18.00
Spontaneous	5	10.00
With D&C	4	8.00
Twin gestation	1	2.00

Past history of the patients analyzed, which showed that 6 (12%) women had one or more previous LSCS. Nine women (18%) had undergone abortions previously, out of which 4 women (8%) had D&C done. The incidence of twin gestation in the present study was in 1-case (2%).

**Table -5 Route of delivery: Abdominal**

Route of delivery	No. of cases	Percentage
Pregnancy	38	76.00
Elective	3	6.00

**Table -6: Route of delivery: Vaginal**

Route of delivery	No. of cases	Percentage
Augmented with oxytocin	3	6.00
Spontaneous	6	12.00

9 cases (18%) delivered vaginally. In the vaginal delivery group, 3 cases (6%) were augmented with oxytocin and had no perinatal mortality, while 6 had spontaneous delivery, with perinatal mortality of 33%.

Mean duration of prolongation of hospital stay with expectant management was 6 days.

**Table-7 Maternal Hemoglobin at Admission**

	<5gm	5-7gm	7-9gm	9-10gm	>10gm
No. of Cases	8	8	17	4	13
Percent	16.00	16.00	34.00	8.00	26.00

Mean hemoglobin percent = 7.8 gm

Statistically 16 cases (32%) of women presented with severe anemia (Hb% < 7g%) and 8 cases (16%) had hemoglobin <5 gms and the mean hemoglobin was 7.8 gms. Lowest hemoglobin recorded was 3.5 gms. Eight (8) cases presented with shock i.e., 16% of women needed acute emergency care.

**Table -8 : Correlation of hemodynamic status at admission and perinatal outcome**

	Minor type of placenta previa		Major type of placenta previa	
	No.	Perinatal mortality	No.	Perinatal mortality
Patients in shock	-	-	8	5
Patients not in shock	23	4	19	5

$\chi^2=5.62$  p<0.05 Significant

All the cases in shock were of major degree of placenta previa and perinatal mortality was 62%. Hence, there is a significant higher

perinatal mortality seen in patients presenting with shock when compared to patients presenting with stable vital parameters.

**Table -9 Blood Transfusion**

	No. of pints of blood transfusions			
	1	2	3	4
No. of Patients	7	15	6	1

Mean =2.03 units

29 cases (58%) of the women admitted required blood transfusion in quantities as per their general condition. A total of 59 units of blood were transfused, hence mean units transfused per percent is 2.03.

**Table-10: Blood transfusion in antepartum, intrapartum and postpartum**

Period	No. of units blood	Percent	No. of patients	Percent
Antepartum	06	10.00	03	06.00
Intrapartum	04	6.70	02	04.00
Postpartum	49	83.00	24	48.00
Total	59	100.00	29	100.00

Out of the 29 (58%) cases requiring blood transfusions, 3 (6%) cases received blood antenatally, 2 (4%) cases received blood intrapartum and 24 (48%) women received blood in postpartum. 8 (16%) women required blood transfusion but, were unable to arrange and were hemodynamically stable in the puerperium. They were given parental iron therapy with iron sucrose in calculated doses.

**Table-11: Correlation of maternal Hb with perinatal outcome**

	Hb in grams				
	<5	5-7	7-9	9-10	>10
No. of patients	8	8	17	4	13
Perinatal mortality	5	4	3	1	1
Percent	62	50	17	25	7.6

$\chi^2$  4.81 p,0.05

significant

The above results prove that, there is a high perinatal mortality in women with severe anemia (<7 gms), and this association with the  $\chi^2$  test is significant statistically.

**Table-12: Mode of delivery and perinatal mortality**

	Vaginal (all cases of minor placenta previa) (n=9)		LSCS (major-26 and minor-15 PP) (n=41)	
	Spontaneous	Augmented with pitocin	Emergency	Elective
No. of patients	6(12%)	3(6%)	38(76%)	3(6%)
Perinatal mortality	2(13%)	0	12(87%)	0

We allowed only those cases of minor placenta previa admitted in labor and who were not bleeding actively to deliver vaginally. Five cases were managed expectantly, out of which 3 cases were taken for elective LSCS. Two cases went for emergency LSCS, while remaining 38 (76%) cases had major placenta previa with severe to moderate PV bleeding, and were taken for emergency LSCS irrespective of the gestational age; for maternal safety. There is no significant difference in the perinatal outcome with the mode of delivery; whether vaginal or LSCS. This can be explained, as only patients in second stage of labor or with minor placenta previa and not actively bleeding were allowed vaginal delivery where as, all critical patients and those women with major placenta previa were taken for emergency LSCS immediately. Hence, the outcome is biased and cannot be authenticated with our belief that emergency LSCS is the treatment of choice in major placenta previa in patients with critical hemodynamic state.

Neonatal Outcome: At the time of delivery 39 (78%) cases gave birth to live neonates, 11(22%) cases had still born babies and 3 (6%)

neonates died in the early neonatal period.

**Table -13: Condition of fetus at birth**

Outcome	Maturity & Mode of Delivery				Total	Percent
	Term (n=5)		Preterm (n=5)			
	LSCS	Vaginal	LSCS	Vaginal		
Alive	3	0	29	7	39	78
IUD	1	1	8	1	11	22

Among the 11 IUD, 9 (81%) cases were preterm newborns clearly depicting that prematurity is one of the most important factor responsible for neonatal death with placenta previa.

**Table -14: Perinatal morbidity**

Morbidity	Term	Preterm	Total	Percent
Resuscitation	1	23	24	48.00
NICU admission	--	12	12	24.00

In the present study, 24 (48%) babies receive resuscitation out of which 23 (46%) babies were premature and 1 (2%) baby was a term neonate. NICU admission in 12 (24%) babies, all of which were premature.

**Table-15: Apgar score according to gestational age and management protocol**

Apgar score	Gestational age (Weeks)					
	28-33		34-36		37 & above	
	Active	Expectant	Active	Expectant	Active	Expectant
At 1 min	4.4±1.8	5.5±1.5	5.26±1.6	6.5 ±0.5	5.0±2.0	7.00
At 5 min	7.67±1.4	7.0±1.0	8.13±0.9	9.0±0.00	7.0±1.0	9.00
t' at 1 min	1.1	p>0.05 NS	2.4	P<0.05. S	--	--
t' at 5 min	0.09	p>0.05 NS	4.1	P<0.05 S	--	--

The above table indicates that the perinatal care is lacking in cases of preterm babies and hence, there is no significant difference in the Apgar scores between the actively and expectantly managed babies in the age group of 28-33 weeks. At the same time, the outcome is better with expectantly managed babies in the age group of 34-36 weeks of gestation.

**Table -16: Neonatal outcome in the live born fetuses**

Neonatal outcome	Term	Preterm	Total	Percent
No. of neonates requiring no resuscitation	3	23	26	52.00
26 (52%) cases of neonates required no resuscitation. Out of the 12 (24%) premature babies shifted to NICU, 3 (6%) babies died within 48 hours and 9 (18%) babies recovered and shifted to mother's side. The perinatal mortality in the present study is 28%.				
NICU admissions		12	12	24.00
Expired within 48 hours		3	3	6.00
Recovered		9	9	18.00

**Discussion**

1. In the present study, 50 cases of placenta previa were studied regarding the type of clinical presentation, the clinical course, the perinatal and maternal outcome. The information obtained was analyzed statistically.

2. In this study, it was observed that the incidence of APH was 4.9% out of the total number of deliveries and placenta previa contributed to 37% of cases of APH.

3. In the present study the cases of placenta previa were highest in the maternal age group of 20-29 years i.e., 70%. It was 16% in the age group 30-35 years, 12% in the age group >35 years and 2% in the age group of <19 years. The mean age ± SD in the present study was 25.96

± 4.7 years.

4. In the present study, incidence of placenta previa was highest (56%) in the multiparous (2-3 viable births) group. It was 24% in the grand multi group (>4 viable births) and 10% in the primi group.

5. In the present study, the risk factors studied were cesarean section, abortion and twin gestation. The incidence of prior cesarean section was 12%, prior abortion was 18% and twin gestation in present pregnancy was 2%.

6. Of the complications studied, in the present study severe anemia (<7gm%) contributed to 32%, malpresentation contributed to 14% and PIH was found in only 2% of cases.

7. In the present study 58% of cases required blood transfusion and shock! hypotension was noticed in 12% of cases, PPH was noticed in 10% of cases. In one case B-lymph was utilized to control intraoperative atonic PPH and in 2 cases Cho's multiple hemostatic sutures used for the bleeding from the placental site. Post-operative febrile morbidity was seen in 16% of cases and sepsis complicated 6% of cases.

8. In the present study, perinatal morbidity was studied as the percentage of babies requiring resuscitation and NICU admission. It was 48% and 24% respectively.

9. In the present study, the percentage of perinatal deaths was 28%. Prematurity was the major contributor to perinatal deaths i.e., 42.85% followed by RDS 28.5%, and aspiration contributed to 14.2% each.

10. The perinatal mortality was the same in both the clinical types of placenta previa i.e., chi square value was 1.26, which is not significant.

11. The perinatal mortality was more in the 28-33 weeks gestation group i.e., 51.6% whereas in the 34-36 weeks and 37+ weeks gestation group, it was 34.28% and 14.28%. The chi square value was 12.1, which is highly significant.

12. Infants with birth weights above 2500 grams had a good survival rate and infants with birth weight <1000 grams had a very poor survival rate

**Conclusion**

In the present study, the incidence of antepartum hemorrhage was 4.9% and placenta previa contributed to 37% of cases. The general perinatal mortality was 81 per 1000 live births and that due to placenta previa was 280 per 1000 live births i.e., approximately 4 time higher than the general perinatal mortality rate. The maternal mortality rate due to placenta previa in this study was nil but maternal morbidity was high i.e., more than 60% of cases had antenatal, intranatal and/or postnatal complications and anemia worsened the clinical state of the Patients.

As the maternal and perinatal morbidity and mortality due to placenta previa is preventable, efforts should be made to bring down these rates. This can be achieved by better spacing in between pregnancies, limitation of family size, antenatal registration of all pregnant women, routine use of USG in pregnancy and early referral of high risk pregnant women to tertiary care centres. Awareness should be brought about in the urban sluths and rural public to avail the facilities provided by the government.

These measures will definitely help in a better outcome for both mother and fetus in all high-risk pregnancies.

**References**

1. Razia Mehboob, Nazir Ahmed. Maternal and fetal outcome in placenta previa.

- Pakistan J Med. Res. 2003; 42(1).
2. Emily Olive, Christing L, Robert S, Charles S, Albert and Jonathan MM. Placenta previa: Maternal morbidity and place of birth. *Auz & NZ J of Obstet & Gynecol.* 2005; 45(6): 499-504.
  3. Gorodeski IG, Bahari CM. The effect of placenta previa localization upon maternal and neonatal outcome. *International Journal of Perinatology.* 1987; 15: 169-77.
  4. Bhide A, Prefumo F, Moore J et al. Placental edge to internal os distance in late trimester and mode of delivery in placenta previa. *Br J Obstet & Gyn India.* 2003; 39: 517.
  5. Erin L Butler, Jodi S, Dashe, Ronald MR. Association between MSAF and adverse outcome in pregnancy with placenta previa. *3 Obstet & Gynecol.* 2001; 97(1): 37-38.
  6. Harvey A, Gabert. Correlation between placenta previa and fetal growth. *Am J Obstet & Gynecol.* 1971; 38: 403-406.
  7. McShane PM, Heyl PS, Epstein MF. Maternal and perinatal morbidity resulting from placenta previa. *3 Obstet & Gynecol.* 1985; 65: 176-182.
  8. Tariq Khasbhoggi, Arab Board. Correlation of placenta previa with maternal and neonatal outcome. *Ann Saudi Med.* 1995; 15(4).
  9. Taylor YM, Peacock S, Kramer TL, Vaughan. Placenta previa in Asian origin women: Incidence & Outcome. *Intl J Obstet & Gynecol.* 1995; 86: 805-808.
  10. Edward T Way, Angie Mallozzi, Toan F. Rodis, James FX, Egan Antohny M, Vintzilios, Winstler AC. Association of baby weight with gestational age in placenta previa. *Intl J Obstet & Gynec.* 1996; 90: 120-128.
  11. Ananth CV, Wilcox AJ, Savintz DA, Boes WAT. Relationship between PIH and placenta previa and risk of placenta previa with LSCS, sex of the offspring and smoking. *Am J Obstet & Gynecol.* 1997.
  12. Joan MG, Crane Michel C, Van D, Linda D, Anthony A, Robert L. Neonatal outcome in placenta previa. *Am J Obstet & Gynecol.* 1999; 93: 541-544.
  13. Buttler, Erim, Dashe, Ramus, Ronald. Association between maternal serum alfa-feto protein and adverse outcome in pregnancy with placenta previa. *Intl 3 Obstet & Gynecol.* 2001; 97(1): 35-38.
  14. Sheiner E, Shoham-Vardi I, Hallak M, Hershkowitz R, Katz M, Mazor M. Placenta previa: Obstetric risk factor and pregnancy outcome. *3 Maternal & Fetal Medicine.* 2001; 10(61): 414-419.
  15. Gillian, Melessa, Rosenberg, Deberan. Association of placenta previa with higher number of previous LSCS and parity. *Intl J Obstet & Gynecol.* 2002; 99(6): 976-980.
  16. Ananth CV, Mullian S, John C, Vintzilios Anthony M. Association of placenta previa with prematurity and growth restriction and neonatal mortality. *Am J Obstet & Gynecol.* 2003; 188(5): 1299-1304.
  17. Tuzovic L, Djelmis J, Iljic M. Obstetric risk factors in placenta previa. *Croat Med J.* 2003; 44: 727-733.
  18. Handler AS, Mason ED, Rosenberg DL. Relationship between exposure during pregnancy to cigarette smoking and cocaine use and placenta previa. *Am J Obstet & Gynecol.* 1994; 170: 884.
  19. Sharma AS, Gupta VI. Tocolytic therapy in conservative management of symptomatic placenta previa. *Intl J of Obstet & Gynecol.* 2004; 84(2): 109-113.
  20. Jackson RA, Gibson KA, Wu YW, Croughan MS. Perinatal outcomes in singletons following in vitro fertilization: A meta-analysis. *Intl J Obstet & Gynecol.* 2004 Mar; 103(31): 551-63.
  21. Emily C Olive, Christine L, Roberts Charles 5, Algert & Jonatha MM. Placenta previa: Maternal morbidity and place of birth. *Aus & NZ J Obstet & Gynecol.* 2005; 45(6): 499-504.
  22. Richard LN. Abruptio & placenta previa frequency, perinatal outcome and cigarette smoking. *Intl J Obstet & Gynecol.* 2005; 106(5): 986-991.
  23. Oyeue, Yinka, Smiltian J. Placenta previa, placenta accreta, vasa previa. *Intl J Obstet & Gynecol.* 2006; 107(9): 927-941.
  24. Ananth CV, Wilcox AJ, Cavitt DA, Bowes WA Jr, Luther ER. Effect of maternal age and parity on risk of uteroplacental bleeding in pregnancy. *Intl J Obstet & Gynecol.* 2006; 2: 511-6.
  25. Allen VM, Wilson RP, Cheung A. Pregnancy outcome after assisted reproductive technology. Reproductive Endocrinology Infertility Committee (SOGC). *Intl J Obstet & Gynecol.* Canada. 2006; 28(3): 220-250.
  26. Jaswal A, Manaktala U, Sharma JB. Cervical encirclage in expectant management of placenta previa. *Intl J Obstet & Gynecol.* 2006; 93(1): 51-2.
  27. Gobman, William, Gorschov, Landon, Mark, Sporg et al. Correlation of number of previous LSCS and placenta previa. *Intl J Obstet & Gynecol.* 2007; 110(6): 1249-1255.
  28. Quiying Yang, Shi Wu, Yen, Sharon Caugh YJ, Daniel, Krewski, Lumingsum, Mark C Walker. Placenta previa: Its relationship with race and the country of origin among Asian Women. *Acta Obstetrica & Gynecologica Scandinavica.* 2008; 87(6): 612-616.
  29. Savita Rni, Singhal, Nymphaea, Smitinanda. Maternal and perinatal outcome in APH. *Intl J Obstet & Gynecol.* 2008; 9(2).
  30. Konje JE, Raylor DJ. Bleeding in pregnancy. In James DK, Steer PJ, Weiner CP, Gonik B, editors. *High risk pregnancy management options.* 2nd ed. London: Harcourt 2000.
  31. Dutta DC. Antepartum hemorrhage. In: Konar HL editor. *Textbook of Obstetrics.* 6th ed. New Central Book Agency, Kolkatta 2006: 243-46.
  32. Neilson JP. Antepartum hemorrhage. In: Edmonds DK editor. *Dewhursts Textbook of Obstetrics & Gynecology for postgraduates.* 6th ed. Blackwell Scientific London, Oxford 1995: 164-74.
  33. Arora R, Devi U, Majumdar R. Perinatal morbidity and mortality in antepartum hemorrhage. *J Obstet Gynec India.* 2001; 51(3): 102-4.
  34. Das B. Antepartum hemorrhage in three decades. *J Obstet Gynec India.* 1975; 25: 636-7.
  35. Motwani MN, Sheth J, Narvekar NM, Pundare MC, Hansotia MD. Maternal mortality resulting from antepartum hemorrhage — Review of 20 years. *3 Obstet Gynecol India.* 1989; 39: 364-6.
  36. Khosla A, Dahiya V, Sangwan K, Rathore S. Perinatal outcome in antepartum hemorrhage. *J Obstet Gynecol India.* 1989; 9: 71-3.
  37. Krohn M, Voigt L, McKnight B, Doling JR, Starzyk P, Benedetti TJ. Correlates of placenta abruptio. *Br J Obstet Gynecol.* 1987; 94: 333-40.
  38. Demissie K, Brekenridgen MB, Joseph L, Rhoads GG. Placenta previa: Preponderance of male sex at birth. *Am J Epidemiol.* 1999; 149: 824-30.
  39. Macafee CGH. Placenta previa — study of 174 cases. *J Obstet Gynecol Br Emp.* 1945; 52: 313.
  40. Dommissie J. Placenta previa and intra-uterine growth retardation. *S Afr Med J.* 1965; 67: 291-2.
  41. Spinillo A, Fazzi B, Stronati M, Ometto A, Capuzzo E, Guaschino S. Early morbidity and neurodevelopmental outcome in low-birth weight infants born after third trimester bleeding. *Am J Perinatol.* 1994; 11: 85-90.
  42. Crowley P. Corticosteroids prior to preterm delivery. In: Enkin MW, Keirse MJNC, Renfrew MJ, Neilson JP eds. *Pregnancy and childbirth module, "Cochrane Database of Systematic Reviews", Review No. 02955, August 14; 1994. Disk Issue 1, Oxford Update Software, 1994.*
  43. Merciere CE, Soll RF. Clinical trials of natural surfactant extract in respiratory distress syndrome. *Clin Perinatol.* 1993; 20L: 711-35.
  44. Ratnam SS et al. *Obstetrics & Gynecology for Postgraduates.* 2<sup>nd</sup> edition India. Orient Longman. 2007; 78-88.
  45. Fernando Arias. *Practical guide to high-risk pregnancy and delivery.* 3rd edn. USA, Elsevier. 2008: 333-342.
  46. *Saunders's High Risk Pregnancy Management Options.* 3rd edn. London. WB Saunders. 2000: Chapter-8: 111-117.
  47. *Oxorn Footo's Human Labour & Birth.* 5th edn., USAQ McGraw Hill. 2000: 19,20, 499-503.
  48. *Mudlair and Menon's Clinical Obstetrics.* 10th Edn., India. Orient Longman. 2006: 165-168.
  49. Barret 3 et al. Induced abortion — A risk factor for placenta previa. *Am J Obstet Gynec.* 1981; 141: 769-772.
  50. Brenner W et al. Characteristics of patients with placenta previa and results of expectant management. *Am J Obstet Gynec.* 1978; 132: 180-189.
  51. Campbell S. *Ultrasound in obstetrics and Gynecology.* 1992.
  52. Chervanek F et al. 1984. Role of attempted vaginal delivery in the management of placenta previa. *Obstet & Gynecol.* 1984; 64: 798-801
  53. Cotton D et al. The conservative aggressive management of placenta previa. *Am J Obstet Gynecol.* 1980; 137: 687-695
  54. D'Angelo et al. Conservative management of placenta previa. A cost benefit analysis. *Am J Obstet Gynecol.* 1983; 149: 320-326.
  55. FanneD et al. Vaginal USG for diagnosis of placenta previa. *Am J Obstet Gynec.* 1988; 159: 566-569.
  56. George Macones et al. Association between maternal cocaine use and placenta previa. *Am J Obstet Gynecol.* 1997; 177: 1097-1100.
  57. Gofferfeld K et al. Ultrasonic placentalography: A new method for placental localization. *Am J Obstet Gynecol.* 1966; 96: 538-547.
  58. Grimes D et al. Legal abortion and placenta previa. *Am J Obstet Gynecol.* 1984; 149: 501-504.
  59. Hemmadi et al. Recent trends in the management of placenta previa. *md 3 Obstet Gynecol.* 1989; 39(71): 365-368.
  60. Ian Donald: *Textbook of practical obstetric problems.* Fifth Edition, pp. 423-454.
  61. Iyasu et al. Epidemiology of placenta previa in the United States. *Am J Obstet Gynecol.* 1993; 168: 1424-9.
  62. James Comearin et al. Early placenta previa and delivery outcome. *Obstet Gynecol.* 1983; 61: 577.
  63. Lavery PL. Placenta previa. *Clinics of Obstet & Gynecol.* 1990; 33: 414-421.
  64. Leerenvelt et al. Accuracy and safety of TVS localization of placenta. *Obstet Gynecol.* 1990; 76: 759-762.
  65. Mabie WC. Placenta previa. *Clinical Perinatology.* 1992; 19: 425-435.
  66. McClure et al. Early identification of placenta previa. *Br J Obstet Gynecol.* 1988; 159: 566-569.
  67. Michelle A Williams Ct et al. Increasing maternal age as a determinant of placenta previa. *3 of Rep Med.* 1993; 38(6): 425-428.
  68. Myerscough PR. *Munrokr's operative obstetrics.* 10th Edn., 1982.
  69. Newton E et al. The epidemiology and clinical history of asymptomatic mid-trimester placenta previa. *Am J Obstet Gynecol.* 1984; 149: 743-746.
  70. Patricia M McShane et al. Maternal and perinatal morbidity resulting from placenta previa. *Obstetrics Gynecology.* 1985; 65(2) 176-182. V
  71. Richard Naeye. Abruptio placenta and placenta previa frequency, perinatal mortality and cigarette smoking. *Obstet Gynecol.* 1980; 55(6): 701-704.
  72. Reddi P Rani et al. Placenta previa — An analysis of 4 year experience. *Indian J of Obstet Gynecol.* 1999; 19(3): 53-55.
  73. Rose GL et al. Etiological factors in placenta previa a case controlled study. *Br J Obstet Gynecol.* 1986; 93: 586-588.
  74. Sand H. Ultrasonic diagnosis of placenta previa. *Acta Obstet Gynecol Suppi.* 1997; 56: 105-108.
  75. Silver et al. Placenta previa aggressive expectant management. *Am J Obstet Gynecol.* 1984; 156: 15-21.
  76. Singh P et al. Placenta previa and prior cesarean section. *Acta Obstet Gynecol.* 1981; 60: 367-368.
  77. Steven Clark et al. Placenta previa! Accreta and prior cesarean section. *Obstet Gynecol.* 1985; 66: 89.
  78. Strong T Ct, et al. Placenta previa in twin gestation. *J of Rep Med.* 1989; 34: 415-416.
  79. Studd. *Progress in obstetrics and gynecology.* Vol. 11, pp. 161-178.
  80. Timor Trisch et al. confirming the safety of TVS in patients suspected of placenta previa. *Am J Obstet Gynecol.* 1986; 154: 565-569.
  81. Varma T. The implication of a low implantation of placenta detected by USG in early pregnancy. *Acta Obstet Gynecol Scand.* 1981; 60: 265-268.
  82. Victoria Taylor et al. Placenta previa and prior cesarean delivery — How strong is the association. *Obstet Gynecol.* 1994; 84: 55-7.
  83. Victoria Taylor et al. Placenta previa in relation to induced and spontaneous abortion — A population based study. *Obstet Gynecol.* 1993; 82: 88-91.
  84. Williams M. Cigarette smoking in pregnancy in relation to placenta previa. *Am J Obstet & Gynecol.* 1991; 165: 28-32.
  85. Wolf E et al. Placenta previa is not an independent risk factor for a small for gestational age infant. *Obstet Gynecol.* 1991; 77: 707-709.
  86. Zhang J et al. Maternal age and placenta previa — A population based study. *Am J Obstet Gynecol.* 1993; 168: 641-645.
  87. *Williams Textbook of Obstetrics,* 22<sup>nd</sup> Edn. USA, McGrawhill. 2005: 819-823.
  88. *Tumbulls, Obstetrics.* 3rd edition. Edinburgh. Churchill Livingstone, Elsevier. 2004: Chapter-14: 214-220.